Document:

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

Exhibit 10.3

 

Execution Version

 

AMENDMENT NO. 1 TO LICENSE AGREEMENT

 

This Amendment No.
1 to License Agreement (this “Amendment”) is made as of December 13, 2016, by and among Opiant Pharmaceuticals,
Inc. (formerly known as Lightlake Therapeutics Inc.), a Nevada corporation (“Opiant”), and Adapt Pharma Operations
Limited, an Irish limited company (“Adapt”). Opiant and Adapt are sometimes referred to herein individually
as a “Party” and collectively as the “Parties”. Capitalized terms used but not defined herein
have the meanings given to them in the License Agreement (as defined below).

 

RECITALS

 

WHEREAS, the Parties
entered into a License Agreement, dated as of December 15, 2014 (including the exhibits and schedules thereto, the “License
Agreement”), pursuant to which Opiant licenses to Adapt certain intellectual property rights to develop and commercialize
Products in accordance with the terms and conditions set forth therein;

 

WHEREAS, Section 11.9
of the License Agreement provides that no amendment or modification to the License Agreement shall be binding upon the Parties
unless in writing and duly executed by authorized representations of both Parties; and

 

WHEREAS, the Parties
desire to amend, modify and supplement the License Agreement in the manner specified in this Amendment.

 

NOW, THEREFORE, for
other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Parties hereby agree as follows:

 

1.           Amendment
to Lightlake References.  Each instance of “Lightlake” appearing in the Agreement, including where such word
is used as part of other defined terms, but excluding instances where such word is used as part of “Lightlake Therapeutics
Inc.”, is hereby replaced with “Opiant”.

 

2.           Amendment
to Section 1.11 of the License Agreement. Section 1.11 of the License Agreement is hereby deleted in its entirety and replaced
with the following:

 

“1.11         “Commercial
Sublicensee” means a Sublicensee to whom Adapt has granted a right to offer for sale, have sold or sell one or more Products
in all or a portion of the Territory including exclusive distributors, but excluding (i) Persons who Manufacture Product(s) or
any element thereof and sell such Product(s) only to or at the direction of Adapt, Sublicensees or any of their respective Affiliates,
(ii) wholesalers, (iii) pharmacies, (iv) Persons comprising the First Responder Market, (v) any Person performing third party logistics
or warehousing services on behalf of Adapt or its Affiliates or Sublicensees, and (vi) any other Person who does not have any obligation
to make an upfront, milestone, royalty or similar payment with respect to the applicable Products.”

 

     

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

3.           Amendment
to Section 1.30 of the License Agreement.  Section 1.30 of the License Agreement is hereby amended by deleting clause
(i) thereof and replacing such clause (i) with the following:

 

“(i)
is sold by a Third Party (or any of such Third Party’s direct or indirect licensees or sublicensees) that is not a licensee
or a Commercial Sublicensee of Adapt or its Affiliates (A) in the United States, under an Abbreviated New Drug Application (ANDA),
(B) in the European Union, pursuant to a provision of Articles 10, 10a or 10b of Parliament and Council Directive 2001/83/EC as
amended (including an application under Article 6.1 of Parliament and Council Regulation (EC) No 726/2004 that relies for its content
on any such provision), or (C) in any other country or jurisdiction, pursuant to all equivalents of such provisions”.

 

4.           Amendment
to Section 3.3.1(b) of the License Agreement. Section 3.3.1(b) of the License Agreement is hereby amended by (a) deleting the
phrase “recall,” from the first sentence thereof and (b) deleting the word “such” from the second sentence
thereof.

 

5.           Amendment
to Section 3.5.2 of the License Agreement. Section 3.5.2 of the License Agreement is hereby amended by deleting the first sentence
thereof and replacing such sentence with the following:

 

“Once
a Product receives all requisite Regulatory Approvals in the United States necessary to Commercialize such Product therein,
Adapt shall use Commercially Reasonable Efforts to Commercialize such Product in the United States.”

 

6.           Amendment
to Section 3.6.2 of the License Agreement. Section 3.6.2 of the License Agreement is hereby amended by deleting the words “and
Commercial Sublicensees” from the first sentence thereof.

 

7.           Amendment
to Section 4.3.1 of the License Agreement. Section 4.3.1 of the License Agreement is hereby deleted in its entirety and replaced
with the following:

 

“4.3.1           Right
to Grant Sublicenses.  Adapt shall have the right to grant Sublicenses (through multiple tiers of Sublicensees). 
Adapt shall cause each Sublicensee to comply with the applicable terms and conditions of this Agreement.  Adapt shall remain
responsible for the performance of its Affiliates and Sublicensees that are granted Sublicenses as permitted herein, and the grant
of any such Sublicense shall not relieve Adapt of its obligations under this Agreement.  With respect to any such Sublicense,
Adapt shall ensure that the agreement pursuant to which it grants such Sublicense (i) does not conflict with the terms and conditions
of this Agreement and (ii) contains terms obligating the Sublicensee to comply with confidentiality and non-use provisions consistent
with those set forth in this Agreement.  With respect to any such Sublicense to a Commercial Sublicensee that grants such
Commercial Sublicensee rights to Commercialize a Product in the United States, Adapt shall use Commercially Reasonable Efforts
to ensure that the agreement pursuant to which it grants such Sublicense contains (A) terms obligating such Commercial Sublicensee
to permit Opiant rights of inspection, access, and audit substantially similar to those provided to Opiant in this Agreement and
(B) terms relating to intellectual property and data ownership consistent with those set forth in this Agreement.  With respect
to any such Sublicense to a Commercial Sublicensee that grants such Commercial Sublicensee rights to Commercialize a Product in
the United States, Adapt shall ensure that the agreement pursuant to which it grants such sublicense contains an exclusivity provision
consistent with that contained in Section 4.6.2.  A copy of any Sublicense agreement with a Commercial Sublicensee
executed by Adapt shall be provided to Opiant within fourteen (14) days after its execution; provided that the financial
terms of any such Sublicense agreement may be redacted to the extent not pertinent to an understanding of a Party’s obligations
or benefits under this Agreement.”

 

    	 	2	 

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

8.           Amendment
to Section 4.3.2 of the License Agreement. Section 4.3.2 of the License Agreement is hereby amended by replacing the first
instance of the word “In” therein with the following:  “Subject to the provisions of Section 10.11,
in”.

 

9.           Amendment
to Section 4.6.2 of the License Agreement. Section 4.6.2 of the License Agreement is hereby deleted in its entirety and replaced
with the following:

 

“4.6.2           During
the term of any agreement pursuant to which a Commercial Sublicensee is granted a Sublicense to sell a Product in the United States
or have a Product sold in the United States, other than as contemplated by this Agreement, each Party shall cause such Commercial
Sublicensee not to (i) directly or indirectly, develop, commercialize or manufacture any Competing Product in the United States,
or (ii) license, authorize, appoint, or otherwise enable any Third Party to directly or indirectly, develop, commercialize
or manufacture any Competing Product in the United States.”

 

10.         Amendments
to Article 6 of the License Agreement.

 

(a)          Section
6.3 of the License Agreement is hereby amended by adding a new Section 6.3.4 thereto, immediately after Section 6.3.3, as follows:

 

“6.3.4           Commercial
Sublicensees. Anything to the contrary herein notwithstanding, Adapt shall have the right to assign its rights and delegate
its obligations under this Section 6.3 with respect to Patents in any country or territory outside the United States to
any Commercial Sublicensee to whom Adapt has granted a right to sell the Product in such country or territory. In such event, Adapt
shall remain responsible for ensuring that such Commercial Sublicensee performs any such delegated obligations in accordance with
the terms of this Section 6.3, as applicable.”

 

(b)          Section
6.4 of the License Agreement is hereby amended by adding a new Section 6.4.5 thereto, immediately after Section 6.4.4, as follows:

 

    	 	3	 

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

“6.4.5           Commercial
Sublicensees. Anything to the contrary herein notwithstanding, Adapt shall have the right to assign its rights and delegate
its obligations under Sections 6.4.2 and Section 6.4.3 with respect to actual or suspected infringement or misappropriation
in any country or territory outside the United States to any Commercial Sublicensee to whom Adapt has granted a right to sell the
Product in such country or territory. In such event, Adapt shall remain responsible for ensuring that such Commercial Sublicensee
performs any such delegated obligations in accordance with the terms of Section 6.4.2 and 6.4.3, as applicable.”

 

(c)          Section
6.5 of the License Agreement is hereby amended by adding the words “As between the parties,” immediately prior to the
first occurrence of “Adapt” therein.

 

11.         Amendment
to Section 7.5 of the License Agreement. Section 7.5 of the License Agreement is hereby amended by deleting the phrase “and
Lightlake shall be provided with a copy of any such Publication in advance of public publication or presentation thereof and Adapt
shall consider in good faith any comments Lightlake may have with respect thereto” from the second sentence thereof.

 

12.         Amendments
to Article 10 of the License Agreement.

 

(a)          Section
10.3 of the License Agreement is hereby amended by adding the following as a new final sentence thereof:  “Notwithstanding
the foregoing, in no event shall Opiant have the right to terminate this Agreement on the basis of any breach of any term hereof
by a Sublicensee or attributable to the action or inaction of a Sublicensee.”

 

(b)          Section
10.4 of the License Agreement is hereby amended by deleting the words “or Commercial Sublicensees” and “or Commercial
Sublicensee” therein.

 

(c)          Section
10.6 of the License Agreement is hereby amended by replacing the first instance of the word “In” therein with the following: 
“Subject to Section 10.11, in”.

 

(d)          Section
10.6.5 of the License Agreement is hereby deleted in its entirety and replaced with the following:

 

“10.6.5        
at Opiant’s request and subject to the terms of any applicable third party agreement, assign to Opiant all right, title
and interest of Adapt in each Product Trademark at Adapt’s expense; and”.

 

(e)          Section
10.10 of the License Agreement is hereby amended by adding “, Section 10.11” after “Section 10.10”
in clause (i) thereof.

 

(f)          Article
10 of the License Agreement is hereby amended by adding the following after Section 10.10 thereof:

 

    	 	4	 

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

“10.11        
Step-In Rights.  If this Agreement is properly terminated by Opiant pursuant to Sections 10.3, 10.4 or
10.5, then, provided that such Commercial Sublicensee is not then in material breach of the agreement pursuant to which
its Sublicense has been granted (the “Sublicense Agreement”), any Commercial Sublicensee may (in its sole discretion),
within thirty (30) days of receiving notice of such termination, upon written notice to Opiant and Adapt, elect to become a direct
licensee of Opiant under rights and terms equivalent to the rights and terms of such Sublicense Agreement, effective from and
after the effective date of such termination of this Agreement; provided that such Commercial Sublicensee shall not have any rights
greater than the rights granted to Adapt under this Agreement and Opiant shall have no obligations under such Sublicense Agreement
to such Commercial Sublicensee in excess of its obligations to Adapt. In the event that this Section 10.11 is invoked in
respect of a particular Commercial Sublicensee, the references to Sublicensees and Commercial Sublicensees in Sections 10.6.3
and 10.6.4 shall thereupon be deemed not to refer to such Commercial Sublicensee in respect of which this Section
10.11 is invoked. If requested by Adapt, Opiant shall enter into a reasonable and customary letter agreement with any Commercial
Sublicensee and Adapt containing terms consistent with this Section 10.11 and other terms reasonably acceptable to Opiant,
Adapt and such Commercial Sublicensee.”

 

13.         Amendment
to Section 11.8.2 of the License Agreement. Section 11.8.2 of the License Agreement is hereby amended by replacing the address
for notice of Opiant set forth therein with the following:

 

If to Opiant, to:

 

Opiant Pharmaceuticals, Inc.

401 Wilshire Blvd., 12th Floor

Santa Monica, CA 90401

Attention: CEO

Facsimile: 1-917-322-2105

 

With a copy (which shall not constitute
notice) to:

 

DLA Piper LLP (US)

1650 Market Street, Suite 4900

Philadelphia, PA 19103

Attention: Fahd M.T. Riaz

Facsimile: 1-215-606-2069

 

14.         Amendment
to Section 11.12 of the License Agreement.  Section 11.12 of the License Agreement is hereby amended by replacing the
word “Covenants” therein with the following:  “Except as otherwise provided in Section 10.11 hereof,
covenants”.

 

15.         Possible
Future Amendments.  If requested by Adapt in connection with the granting of a Sublicense to a Commercial Sublicensee
in respect of Europe and/or the United Kingdom, the Parties shall promptly negotiate in good faith additional amendments to the
License Agreement necessary to implement the changes to the financial terms of the License Agreement that are contemplated on Exhibit
A to this Amendment, or such other terms as the Parties may mutually agree upon in good faith.

 

    	 	5	 

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

16.         References
in the License Agreement. All references in the License Agreement to “this Agreement” shall mean the License Agreement
as amended by this Amendment.

 

17.         Limitation
of Amendment and Affirmation of License Agreement. Except as expressly provided herein, this Amendment shall not be deemed
to be a waiver or modification of any term, condition or covenant of the License Agreement. Any conflict between the terms herein
and in the License Agreement shall be governed by the terms of this Amendment. Except as expressly amended hereby, all terms and
conditions set forth in the License Agreement are hereby affirmed by the Parties and shall remain in full force and effect.

 

18.         Incorporation
by Reference. The provisions of Sections 11.3.1, 11.4, 11.5, 11.6, 11.7, 11.8, 11.10, 11.11, 11.12, 11.13, 11.14, 11.16 and
11.18 of the License Agreement are hereby incorporated by this reference, mutatis mutandis, as if the provisions were fully
set forth herein.

 

[Signature Page Follows]

 

    	 	6	 

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

IN WITNESS WHEREOF, this
Amendment is hereby executed by the authorized representatives of the Parties as of the date first written above.

 

	 	OPIANT PHARMACEUTICALS, INC.

 

	 	By:  	/s/ Roger Crystal
	 	 	Name:  Roger Crystal
	 	 	Title:    Chief Executive Officer

 

	 	ADAPT PHARMA OPERATIONS LIMITED

 

	 	By:  	/s/ David Brabazon
	 	 	Name:   David Brabazon
	 	 	Title:     Director

 

     

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

EXHIBIT A

 

In the event that Adapt
proposes to enter into an agreement with a Commercial Sublicensee who would Exploit a Product in the European Union and/or the
United Kingdom (as applicable, “Europe”), at Adapt’s request, the Parties will negotiate in good faith
to amend the License Agreement as necessary to implement the terms described below.

 

	Term	 	Addition or Modification
	Revenue sharing	 	
        Opiant (or its designee) would share in royalties,
        milestone payments and payments for any supplied Product, less all costs incurred in generating such European revenues (including,
        amongst others, development, regulatory, licensing, safety, supply and distribution costs attributable to Europe) received by Adapt
        from a Sublicensee in Europe (“Europe Net Revenues”) based on the following:

         

        ·     ****%
        of all such amounts, up to $**** of cumulative revenue; and

         

        ·     ****%
        of all such amounts in excess of $**** million in cumulative revenue.

         

        In the event that Opiant (or its
        designee) does not receive the $**** milestone contemplated by Section 5.2.4 of the License Agreement, then the $**** threshold
        contemplated above shall be reduced to $****.

         

        Amounts comprising Europe Net Revenues
        and revenues earned by any Sublicensee in Europe would be excluded for purposes of determining Net Sales on which Opiant (or its
        designee) would otherwise be entitled to royalties under the License Agreement, subject to the provisions set forth below in Global
        Sales Milestones and Royalty Tiers.

         

        Adapt shall make the revenue share
        payments in respect of the Europe Net Revenues to Opiant (or its designee) on a Calendar Quarter basis in accordance with the terms
        of Section 5.6 of the License Agreement and any other written instructions agreed to by Adapt.

	 	 	 
	Global Sales Milestones and Royalty Tiers	 	Europe Net Revenues received by Adapt from any Sublicensee in Europe would be included for purposes of determining Net Sales giving rise to sales-based milestones pursuant to Section 5.3.1 of the License Agreement and for purposes of determining royalty tiers set forth in Section 5.4.1 of the License Agreement.  Sublicensee revenues in Europe would be excluded for purposes of such determinations.

 

     

     

    

 

Confidential Treatment has been requested for portions of this
exhibit. The copy filed herewith omits the information subject to the confidentiality request. Omissions are designated as “****”.
A complete version of this exhibit has been filed separately with the Securities and Exchange Commission.

 

	Term	 	Addition or Modification
	 	 	 
	 	 	
        The $**** Annual Net Sales Milestone Threshold
        specified in Section 5.3.1 of the License Agreement would be changed to $****.

         

        The $**** Annual Net Sales Milestone Threshold
        specified in Section 5.3.1 of the License Agreement would be changed to $****.Exhibit 10.5

 

THIRD AMENDMENT TO SENIOR ADVISOR AGREEMENT

 

This third amendment
(the “Third Amendment”) to the Senior Advisor Agreement by and between Brad Miles (“Miles”)
and Opiant Pharmaceuticals, Inc. (the “Company”), dated January 22, 2013 and amended on February 24, 2015 and
March 19, 2015 is entered into on March 13, 2017 (collectively, the “Agreement”) (the “Effective Date”),
and hereby amends the terms of the Agreement. Company and Miles may be referred to herein as a “Party” or, collectively,
as “Parties”. Capitalized terms used but not defined in this Third Amendment shall have the meaning ascribed
to such term in the Agreement.

 

RECITALS:

 

WHEREAS, the
Company is currently planning on developing a specific product that is not for the treatment of a specific addiction, that the
Company internally references under the name “OPNT003” and that is undergoing a study during Q1 2017 (the “Product”);

 

WHEREAS, Miles
is a Senior Advisor to the Company and in connection with the ongoing services (the “Services”) provided by Senior
Advisor, the Company seeks to grant Miles the following interest in the Product and other compensation as set forth herein.

 

NOW, THEREFORE,
in consideration of the various promises and undertakings set forth herein, the Parties hereby mutually agree to this Third Amendment
as follows:

 

Article
1

DEFINITIONS

 

Unless otherwise specifically
provided herein, the following terms shall have the following meanings

 

		1.1	“Affiliate” means a Person that controls, is controlled by or is under common
control with a Party, but only for so long as such control exists. For the purposes of this Section 1.1, the word “control”
(including, with correlative meaning, the terms “controlled by” or “under the common control with”) means
the actual power, either directly or indirectly through one or more intermediaries, to direct the management and policies of such
Person or entity, whether by the ownership of more than fifty percent (50%) of the voting stock of such entity, or by contract
or otherwise.

 

		1.2	“Divestiture” means a transaction in which the Company sells all intellectual
property rights and regulatory approvals for the Product to a Third Party.  For clarity, a Sublicense is not a Divestiture.

 

		1.3	“FFDCA” means the The United States Federal Food, Drug, and Cosmetic Act and
all amendments thereto.

 

		1.4	“Law” or “Laws” means all applicable laws, statutes, rules,
regulations, ordinances and other pronouncements having the binding effect of law of any governmental body.

 

		1.5	“Net Profit” means any revenue received by the Company that was derived from
Sales of the Product less any and all Product Expenses not previously deducted from revenue received by the Company (“Revenue”). 
For clarity, Product Expenses shall be carried over until actually deducted and netted from Revenue.

 

     

     

    

 

		1.6	“Person” means any natural person, corporation, firm, business trust, joint
venture, association, organization, company, partnership or other business entity, or any government or agency or political subdivision
thereof.

 

		1.7	“Product Expenses” means all costs and expenses incurred by and payments made
by the Company or its Affiliates in connection with generating revenue from the Product, including all costs and expenses incurred
(including allocation of Company overhead based on the proportionate time, expenses and resources devoted by the Company to activities
related to the Product as determined by the Company in good faith) for (a) the research, development and commercialization of the
Product and (b) for any transaction, directly or indirectly, related to the Product.

 

		1.8	“Regulatory Approval” means the approval of a New Drug Application (as defined
by the FFDCA) by the U.S. Food and Drug Administration necessary to commercially distribute, sell, offer for sale, market, import
or use a Product in the United States including, pricing, reimbursement and labeling approval.

 

		1.9	“Sale of the Product” means any transaction for which consideration is received
by the Company for sale, use, transfer or other disposition of a Product to or for the benefit of a Third Party. For clarity, a
Sale of the Product does not include a Divestiture.

 

		1.10	“Sublicense” means a grant to a Third Party of a right under the Company’s
intellectual property rights to make, use or sell the Product.

 

		1.11	“Third Party” means any Person other than the Company, Miles or any of their
respective Affiliates.  

 

		1.12	“Third Party Agreement” shall mean any agreement between the Company and a Third
Party related to the Product, including any assets material to the Product.

 

		1.13	Other Terms. The definition of each of the following terms is set forth in the section of
the Agreement indicated below:

 

	Defined Term	 	Section
	Agreement	 	Preamble
	Audit	 	3.1
	Audited NP	 	3.3
	Buyback Amount	 	2.3
	Company	 	Preamble
	Effective Date	 	Preamble
	Estimated NP	 	3.3
	Fair Market Value	 	2.2
	Interest	 	2.1
	Interest Holder	 	2.5
	Miles	 	Preamble
	Notices	 	4.7
	Party	 	Preamble
	Product	 	Recitals
	Revenue	 	1.4
	Third Amendment	 	Preamble

  

    -ii- 

     

    

 

Article
2

GRANT AND OTHER RIGHTS

 

		2.1	Extension of Term. Miles shall provide the Services and additional Services through December
31, 2017 (the “Term”), unless the Agreement is terminated as per its terms.

 

		2.2	Consideration for Services.

 

		2.2.1	Within fifteen (15) business days of the execution of this Third Amendment, Miles shall be paid
$107,805 and be issued 1,875 shares of the Company’s common stock.

 

		2.2.2	The Company hereby agrees to grant Miles the right to receive, pro rata, 1.25% of the Net Profit
generated from the Product from the Effective Date (the “Interest”). In the event of a Divestiture, Miles shall
receive 1.25% of the net proceeds of such sale, pro rata, and in the form of such net proceeds, after the deduction of Product
Expenses not previously deducted. In the event that the Company is sold, then the Company shall engage an independent financial
or accounting firm to determine the fair value of the Company which is directly attributable to the Product (“Fair Market
Value”) and Miles shall receive 1.25% of such amount after the deduction of all expenses and costs related to such sale.
Upon receipt of the payment described in this Section 2.2, the Interest shall be deemed either extinguished or transferred or sold
back to the Company, at the Company’s direction, and have no further legal effect and Miles shall have no rights with respect
to such Interest.

 

		2.2.3	Subject to the terms of this Agreement, the Company agrees to pay Miles $17,000 per calendar quarter
during 2017. The payment for the first calendar quarter of 2017 shall be made by the Company to Miles no later than fifteen (15)
business days after the execution of this Third Amendment. The $17,000 payments for the second, third and fourth calendar quarters
of 2017 shall be made by the Company to Miles no later than fifteen (15) business days after the start of each respective calendar
quarter.

 

		2.2.4	The Company shall grant Miles warrants (the “Warrants”) to purchase 45,000 shares of
the Company’s common stock (the “Common Stock”) (with each share of Common Stock, a “Share”). All
of the Warrants shall have an exercise price of $10.00, which shall be equal to or greater than the fair market value of a Share
of Common Stock on the date of their grant. All of the Warrants shall be exercisable for cash. All of the Warrants shall contain
standard adjustment provisions with respect to stock splits, recapitalizations, change of control and fundamental transactions
but shall not contain any anti-dilution or price protection. All of the Warrants shall have a three-year life from their date of
grant. Notwithstanding the foregoing, in the event that Miles is terminated by the Company for Cause pursuant to Article IV of
this Third Amendment, then all of the Warrants not previously exercised shall expire on the day of such termination. All of the
Warrants shall fully vest on their grant date. None of the Warrants are transferable except that in the event of Miles’s
death the Warrants shall be transferrable to Miles’s estate.

 

All of the Warrants
shall be in such form as the Form of Notice of Warrant Grant attached as Exhibit A hereto, which Warrants may be exercised, where
applicable, pursuant to the Form of Notice of Exercise of Warrant attached as Exhibit B hereto.

 

Upon the exercise
of such Warrants, the fair market value per Share of Common Stock shall be equal to the closing price of the Shares of Common
Stock of the Company on the day prior to such exercise. Exercise of these Warrants shall occur by Miles’s: (i) surrendering
the exercised Warrants at the principal office of the Company together with a properly completed and signed Notice of Exercise
of Warrant (as per Exhibit B hereto), and (ii) providing via email a readable .pdf or scan of all of the documentation set forth
in (i) to the email addresses of the Chief Executive Officer, Chief Financial Officer and Controller (if the Company has a Controller
at such time) of the Company at the time of such surrender (the current applicable email addresses being: rcrystal@opiant.com
and kpollack@opiant.com).

 

    -iii- 

     

    

 

	2.3	Buyback Right. Notwithstanding any other provisions of this Agreement, from the Effective Date until four (4) years from the Effective Date the Company shall have the right to buyback the Interest or any portion of the Interest by providing written or electronic notice to Miles. Any such notice shall include the percentage amount of the Interest to be bought back by the Company, and such notice shall also include the dollar amount that equals the percentage amount of the Interest to be bought back by the Company based on a rate of 1.25% of Interest being equal to one hundred eighty seven thousand five hundred dollars ($187,500) (the  “Buyback Amount”). In the event that such notice is provided within two and one half (21⁄2) years of the Effective Date, then the Company shall pay Miles two (2) times the Buyback Amount within ten (10) business days of providing such notice. In the event that such notice is provided after two and one half (21⁄2) years from the Effective Date and no later than four (4) years from the Effective Date, then the Company shall pay Miles three and one half (31⁄2) times the Buyback Amount within ten (10) business days of providing such notice. Upon the Company’s paying to Miles the Buyback Amount with respect to the Interest or any portion of the Interest, such Interest or portion of the Interest, as appropriate, shall be deemed either extinguished or transferred or sold back to the Company, at the Company’s direction, and have no further legal effect and Miles shall have no rights with respect to such amount of Interest bought back by the Company.

 

		2.4	Third Party Agreements. Miles agrees that the Company and its successors and assigns may
freely enter into any Third Party Agreement without the prior written consent of Miles.  Further, Miles agrees and covenants
for the benefit of the Company and its successors and assigns, and any Third Party that enters into a Third Party Agreement and
its successors and assigns, and each of their respective shareholders, directors, officers and employees (each, an “Interest
Holder”) that (a) it shall under no circumstances seek payment or other compensation for any amount due hereunder from any
party other than the Company and its successors and assigns, including with respect to any Third Party Agreement and (b) that such
Interest Holders shall be express Third Party beneficiaries of Miles’s covenants in this Section 2.4 and may enforce the
provisions hereof and that the foregoing is a material inducement of such Third Parties to enter into any Third Party Agreement,
if any.  In consideration of Miles agreeing to the consent granted in this Section 2.4, Company agrees and covenants for the
benefit of Miles that in the event that the Company sells a portion of its Revenue stream to a Third Party, Miles’s original
interest in Net Profit shall be adjusted upward to “equally offset” any reduction in the original interest that would
be the result of such sale of the Revenue stream from which Miles would not receive anything.  For example, if ten percent
of Revenue stream is sold and the original share of Miles of Net Profit was 1.25%, then Miles’s share of the Net Profit shall
be adjusted by ten percent to 1.375% of Net Profit.

 

    -iv- 

     

    

 

Article
3

FINANCIAL PROVISIONS

 

		3.1	Net Profit Audit. The Company shall provide Miles with an annual audit of Net Profits (the
“Audit”), which Audit shall be completed after the end of each calendar year.  Notwithstanding the foregoing,
this Section 3.1 shall not be applicable until the Product generates Net Profit from which amounts would be due to Miles.

 

		3.2	Product Status Update. After the end of each quarter of the calendar year, the Company shall
provide Miles with a written or electronic update with respect to the status of the Product.

 

		3.3	Net Profit Distribution. After the end of each of the first three quarters of the calendar
year, the Company shall distribute to Miles eighty percent (80%) of such calendar quarter’s Net Profits represented by the
Interest, which amount shall be estimated in good faith by the Company. Upon the completion of the Audit for such calendar year,
the Company shall distribute to Miles the Net Profits represented by the Interest, for the fourth quarter of the calendar year.
In the event that the Audit for such calendar year determines the Net Profits represented by the Interest, for the first three
quarters of the calendar year (the “Audited NP”) to be greater than the estimated Net Profits represented by
the Interest, actually paid to Miles for the first three calendar quarters (the “Estimated NP”), then the Company
shall distribute to Miles the difference between the Audited NP and the Estimated NP. In the event that the Audit for such calendar
year determines the Audited NP to be less than the Estimated NP, then the Company shall deduct the difference between the Estimated
NP and the Audited NP from the distribution for the fourth quarter of such calendar year and, if required, each following distribution
until such amount is fully deducted.

 

Article
4

ADDITIONAL PROVISIONS

 

		4.1	All compensation granted to Miles herein shall be in addition to compensation previously granted
by the Company to Miles. No other compensation shall be owed or due to Miles unless set forth in this Third Amendment or in the
Agreement.

 

		4.2	Notwithstanding anything herein to the contrary, during the Term, the Company may terminate this
Agreement at any time for Cause (as hereinafter defined). In such an event Miles shall be deemed effectively terminated as of the
time of delivery of such notice. For the avoidance of doubt, there will be no severance pay or other special payment upon such
termination by the Company for Cause and the Company shall not be obligated to provide any further compensation to Miles, except
that Miles shall be entitled to all such options and warrants held by Miles that have vested. For purposes of this Agreement, “Cause”
means: termination based upon Miles’s (i) willful breach or willful neglect of his duties and responsibilities; (ii) conviction
of or a plea of no contest with respect to a felony occurring on or after the execution of this Agreement; (iii) material breach
of this Agreement; (iv) acts of fraud, dishonesty, misappropriation, or embezzlement; (v) willful failure to comply with the Board
of Directors of the Company’s reasonable orders or directives consistent with Miles’s position; or (vi) becoming disqualified
or prohibited by law from serving as Senior Advisor of the Company; provided, however, that in the case of any act or failure to
act described in clauses (i), (iii), or (v) above, such act or failure to act will not constitute Cause if, within ten (10) days
after notice of such act or failure to act is given to Miles by the Company, Miles has corrected such act or failure to act (if
it is capable of correction).

 

    -v- 

     

    

 

		4.3	This Third Amendment, together with any other documents incorporated herein by reference, including
the Agreement, and related exhibits and schedules, constitutes the sole and entire agreement of the Parties with respect to the
subject matter contained herein, and supersedes all prior and contemporaneous understandings, agreements, representations and warranties,
both written and oral, with respect to such subject matter.

 

		4.4	The Agreement, as amended by this Third Agreement, may only be amended, modified, or supplemented
by an agreement in writing signed by each Party to the Agreement or, in the case of waiver, by the Party or Parties waiving compliance.

 

		4.5	This Third Amendment shall be governed by and construed in accordance with the internal Laws of
the State of California without giving effect to any choice or conflict of Law provision or rule. Each Party irrevocably submits
to the exclusive jurisdiction and venue of the federal and state courts located in California in any legal suit, action or proceeding
arising out of or based upon this Third Amendment or the Services and/or compensation provided hereunder.

 

		4.6	If any term or provision of this Third Amendment is invalid, illegal or unenforceable in any jurisdiction,
such invalidity, illegality or unenforceability shall not affect any other term or provision of this Third Amendment or invalidate
or render unenforceable such term or provision in any other jurisdiction.

 

		4.7	This Third Amendment may be executed in multiple counterparts and by facsimile signature or by
email of a PDF document, each of which shall be deemed an original and all of which together shall constitute one instrument.

 

		4.8	All notices, requests, demands and other communications (collectively, “Notices”)
given pursuant to this Agreement shall be electronic or in writing, and shall be delivered by email or by personal service, courier,
facsimile transmission or by United States first class, registered or certified mail, postage prepaid, addressed to the Party at
the address set forth below.  Any Notice, other than a Notice sent by registered or certified mail, shall be effective
when received; a Notice sent by registered or certified mail, postage prepaid return receipt requested, shall be effective on the
earlier of when received or the fifth day following deposit in the United States mails.  Any Party may from time to time
change its address for further Notices hereunder by giving notice to the other Party in the manner prescribed in this Section.
Notwithstanding the foregoing, the Company may send the information set forth in Sections 3.1 and 3.2 via email.

 

	For Company	with a copy to:
	 	 
	
        Opiant Pharmaceuticals, Inc.

        401 Wilshire Blvd., 12th Floor

        Santa Monica, CA 90401

        Attention: Roger Crystal

        Email: rcrystal@opiant.com
	
        DLA Piper LLP

        One Liberty Place

        1650 Market Street, Suite 4900

        Attention: Fahd M.T. Riaz

        Email: Fahd.Riaz@dlapiper.com

	
         

        For Miles:
	 
	 	 
	Brad Miles	 
	117 Sandcherry Court	 
	Pickering, Ontario Canada L1V 6V8   	 
	Email: bmiles@opiant.com or 

    mb.miles@sympatico.ca	 

 

    -vi- 

     

    

 

IN WITNESS WHEREOF,
duly authorized representatives of the Parties have executed this Third Amendment as of the Effective Date.

 

	OPIANT PHARMACEUTICALS, INC.	 	BRAD MILES
	 	 	 	 
	By:	/s/ Kevin Pollack	 	By: 	/s/ Brad Miles
	Name: 	Kevin Pollack	 	Title:	 Senior Advisor
	Title: 	CFO	 	 	 

 

    -vii- 

     

    

 

EXHIBIT A

 

OPIANT PHARMACEUTICALS, INC.

401 Wilshire Blvd., 12th Floor

Santa Monica, CA 90401

 

Form of Notice of Warrant Grant

 

Dear Brad Miles,

 

Pursuant to the Third
Amendment to the Senior Advisor Agreement by and between you and Opiant Pharmaceuticals, Inc. (the “Company”), dated
January 22, 2013 and amended on February 24, 2015, March 19, 2015 and March 13, 2017 (the “Third Amendment”) (collectively,
the “Agreement”), the Company has granted you warrants (the “Warrants”) to purchase common stock of the
Company (the “Common Stock”) (with each share of Common Stock, a “Share”) as follows:

 

	Board Approval Date:	March 11, 2017
	 	 
	Date of Grant:	March __, 2017
	 	 
	Exercise Price per Share:	US$10.00, which shall be equal to or greater than the fair market value of a Share of Common Stock on the Date of Grant.
	 	 
	Total Number of Shares Granted:	45,000
	 	 
	Method of Exercise:	Cash exercise
	 	 
	Expiration Date:	March  [   ], 2020
	 	 
	Termination Period:	Except as otherwise provided below, these Warrants may be exercised for a period of three (3) years from the Date of Grant.  You are responsible for keeping track of these exercise periods.  The Company will not provide further notice of such periods. 
	 	 
	 	Notwithstanding the foregoing, in the event that you are terminated by the Company for Cause pursuant to Article IV of the Third Amendment, then the Warrants shall expire on the day of such termination.  
	 	 
	Transferability:	The Warrants are not transferable except that in the event of your death the Warrants shall be transferrable to your estate.
	 	 
	Restriction on Exercise:	Your ability to exercise these Warrants is contingent on your and your officers, agents, and representatives keeping confidential information shared with you and your officers, agents, and representatives confidential and complying with all applicable laws and regulations.
	 	 
	Vesting:	100% on March __, 2017

 

    -viii- 

     

    

 

These Warrants may only
be exercised for cash.

 

Following receipt by
the Company of evidence and/or an indemnity from you to the Company in a form reasonably satisfactory to the Company of the loss,
theft, destruction or mutilation of these Warrants or any certificates for representing the Shares underlying these Warrants and,
in the event of mutilation, following the surrender and cancellation of such Warrants or stock certificate, the Company shall make
and deliver replacement Warrants or stock certificate of like tenor and dated as of such cancellation, in lieu of these Warrants
or stock certificate, without any charge therefor.  Any such replacement Warrants or stock certificates shall be subject to
the same terms, conditions, and restrictions as these Warrants and any Shares underlying these Warrants. Proportionate adjustments
shall automatically be made to both the Exercise Price and number of these Warrants in the event of a stock split, recapitalization,
change of control and fundamental transaction. Upon the exercise of these Warrants, the fair market value per Share shall be equal
to the closing price of the Shares on the day prior to such exercise.

 

Exercise of these Warrants
shall occur by your: (i) surrendering the exercised Warrants at the principal office of the Company together with a properly completed
and signed Notice of Exercise of Warrant (as per Exhibit B), and (ii) providing via email a readable .pdf or scan of all of the
documentation set forth in (i) to the email addresses of the Chief Executive Officer, Chief Financial Officer and Controller (if
the Company has a Controller at such time) of the Company at the time of such surrender (the current applicable email addresses
being: rcrystal@opiant.com and kpollack@opiant.com).

 

If only a portion of
the Warrants are exercised as of a particular date, the number of Shares issued shall be rounded down to the nearest whole share.
However, the number of Shares issued is rounded up to 100% on the final exercise date with respect to the Warrants.

 

These Warrants may be
delivered to you electronically with a scanned signature, in which case they shall have the same effect and force as if they had
been delivered in original signed form.

 

You shall not have any
of the rights of a stockholder with respect to the Shares of Common Stock until such Shares have been issued to you upon the due
exercise of the Warrants. No adjustment will be made for dividends or distributions or other rights for which the record date is
prior to the date such Shares are issued.

 

This Notice may be amended
from time to time by the Company in its discretion; provided, however, that this Notice may not be modified in a manner that would
have a materially adverse effect on the Warrants or Shares as determined in the discretion of the Company except as provided in
a written document signed by you and the Company.

 

This Notice and the Warrants
granted hereunder are intended to comply with, or otherwise be exempt from, Section 409A of the Code. This Notice and the Warrants
shall be administered, interpreted and construed in a manner consistent with this intent. Nothing in this Notice shall be construed
as including any feature for the deferral of compensation other than the deferral of recognition of income until the exercise of
the Warrants. Should any provision of this Notice be found not to comply with, or otherwise be exempt from, the provisions of Section
409A of the Code, it may be modified and given effect, in the sole discretion of the Company and without requiring your consent,
in such manner as the Company determines to be necessary or appropriate to comply with, or to effectuate an exemption from, Section
409A of the Code. The foregoing, however, shall not be construed as a guarantee or warranty by the Company of any particular tax
effect to you.

 

Notwithstanding the foregoing,
if at any time the Company determines that the delivery of Shares under this Notice is or may be unlawful under the laws of any
applicable jurisdiction, or federal, state or foreign securities laws, the right to exercise the Warrants or receive Shares pursuant
to the Warrants shall be suspended until the Company determines that such delivery is lawful. If at any time the Company determines
that the delivery of Shares is or may violate the rules of the national securities exchange on which the shares are then listed
for trade, the right to exercise the Warrants or receive Shares pursuant to the Warrants shall be suspended until the Company determines
that such exercise or delivery would not violate such rules.

 

    -ix- 

     

    

 

By your signature and
the signature of the Company’s representative below, you and the Company agree to the terms of these Warrants.

 

	 	 	OPIANT PHARMACEUTICALS, INC.
	 	 	 
	 	 	 
	 	 	 
	 	 	Kevin Pollack, Chief Financial Officer

 

    -x- 

     

    

 

EXHIBIT B

 

Form of Notice of Exercise of Warrant

 

Ladies and Gentlemen:

 

This letter constitutes
an unconditional and irrevocable notice that I hereby exercise the warrant(s) granted to me by Opiant Pharmaceuticals, Inc., a
Nevada corporation (the “Company”) on _______________ at a fair market value of US$ ______ per share. Pursuant to the
terms of such warrant(s), I wish to purchase _______________ shares of the common stock covered by such warrant(s) at the exercise
price(s) of US$ ______ per share via cash exercise, for a total aggregate purchase price of US$_______________, which I agree to
promptly provide to the Company.

 

These shares should be delivered as follows:

 

	Name:	 	 
	 	 	 
	Address: 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Tax ID #:	 	 

 

I represent that I will not dispose of such
shares in any manner that would involve a violation of applicable securities laws.

 

	Dated:	 	 	By:	 
	 	 	 	 	 
	 	 	 	Name:	 

 

    -xi-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00268-of-00352.parquet"}]]